BridgeBio Pharma Inc.
Moat Score — BridgeBio Pharma Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | 200+ issued patents and 300+ pending applications protect key assets like Attruby/Beyonttra, plus FDA approvals and orphan/rare-disease designations create real regulatory barriers to entry. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | The hub-and-spoke model gives a genuine R&D cost-efficiency edge (~$40M per program to proof-of-concept) versus typical biopharma R&D spend, though this is an operating efficiency, not a product cost advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As a first-in-class or best-in-class therapy for ultra-rare and rare genetic diseases with little or no approved competition (e.g., ADH1, LGMD2I/R9), BridgeBio can command premium specialty-drug pricing, though ATTR-CM pricing is constrained by Pfizer's and Alnylam's competing therapies. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | No network effects; value comes from clinical efficacy and IP, not from user or participant growth. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once physicians and patients stabilize on a chronic therapy like Attruby, there is some clinical inertia and payer-formulary lock-in, but rival therapies (tafamidis, vutrisiran) remain viable switches. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Rare/ultra-rare disease markets (e.g., ADH1's ~25,000 carriers, LGMD2I/R9's ~7,000 patients) are small enough that they may not support multiple profitable entrants, giving some natural-limited-scale protection in those niches, though its largest market (ATTR-CM) is large and crowded. |